Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
NCT03093909Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2017
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gemcitabine in solid tumor, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Toxicities at 24 weeks. Started Nov 2017; status: recruiting.
02
Drugs
gemcitabine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03093909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03093909.